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Tight glycemic control models for critically ill patients 
in intensive care units 
 
Critically ill patients often present stress-induced hyperglycemia and low insulin sensitivity [1]. Recent studies have shown 
that high blood glucose (BG) levels are linked to worsened patient outcomes and increased mortality [2, 3]. Tight glycemic 
control (TGC) aims at reducing BG levels taking into account inter-patient variability, evolving physiological patient conditions 
and minimizing hypoglycemic risks. Clinical protocols are used to specify insulin and nutrition rates and BG measurement 
frequency during control. This research compares different protocols to determine the best one to use at the CHU of Liege. 
 
Introduction 
 
The STAR-Belgium controller is the best clinical protocol 
for TGC in this study. We have shown it is highly effective 
and safe. Pilot trials are currently underway to assess its 
control performance in real clinical conditions. 
Conclusions 
 
sophie.penning@ulg.ac.be 
tdesaive@ulg.ac.be 
geoff.chase@canterbury.ac.nz 
Contacts 
 
Initial results : better performance for the Targeted and 
STAR controllers.  
 
Two main problems with the STAR controller : 
1. Aggressiveness, increasing the risk of hypoglycemia (BG 
< 40 mg/dL)  nutrition rates can be increased & limit 
the insulin rate changes; 
2. Controller differences, harmful to comparison quality  
define new BG target of 144 mg/dL and allow 2-hourly 
measurement 
 
The resulting controller, STAR-Belgium, has the lowest 
percent of hypoglycemic events and provides the tightest 
control around its BG target illustrated by the steeper BG 
cumulative density function (CDF) in Figure 1 and in Table 2.  
Results 
Table 2 – Virtual trial results: whole cohort statistics  
Figure 1 – Comparison of BG CDF for Glucontrol B (blue line) 
and STAR-Belgium (green line) controllers, for whole cohort 
% BG Glucontrol B STAR STAR-Belgium 
< 40 mg/dL 0.054 0.062 0.020 
> 180 mg/dL 24.1 6.8 12.9 
in 140-180 mg/dL 42.4 8.5 50.1 
in 120-160 mg/dL 39.33 67.96 58.43 
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We compare three protocols described in 
Table 1. Glucontrol B is a experimental 
protocol while Targeted and STAR 
controllers are model-based. Moreover, 
STAR controller uses a stochastic model 
accounting for hour-to-hour patient 
variability.  
 
 
 
Methods 
Controller performance was tested in virtual trials using Glucontrol retrospective clinical data and the glucose-insulin model. 
STAR was adapted to Belgian ICU requirements to create STAR-Belgium. 
Table 1 – TGC protocols description  
% BG Glucontrol B Targeted/STAR controllers 
Origin Belgian protocol Designed for Christchurch, NZ 
Features Experimental sliding scale Adaptive, model-based predictive controller 
BG target 140 – 180 mg/dL 90 mg/dL 
BG measurement  
frequency 
1 – 4 hours 1 hour 
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